The federal government is subsidising a new drug for Australians suffering with a rare, fatal heart condition through Pharmaceutical Benefits Scheme (PBS).
From February 1, Uptravi (selexipag) will be PBS listed for the first time to treat Pulmonary Arterial Hypertension (PAH), for use in combination with existing therapies, Health Minister Greg Hunt said in a statement on January 31.
